Yamada Jun, Sugimoto Yumi, Yamada Shizuo
Department of Pharmacology, Kobe Pharmaceutical University, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan.
Eur J Pharmacol. 2004 Nov 19;504(3):207-11. doi: 10.1016/j.ejphar.2004.09.057.
The effects of dopamine re-uptake inhibitors, bupropion and nomifensine on immobility in the forced swimming test were studied in mice. Bupropion and nomifensine reduced immobility time dose-dependently. Both drugs significantly displayed anti-immobility effects at doses without altering locomotor activity. Anti-immobility effects of bupropion and nomifensine were inhibited by the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-HCl (SCH 23390) and the dopamine D2 receptor antagonist sulpiride. These findings suggest that dopamine may be related to depression and dopamine D1 and dopamine D2 receptors play a role in the effects of dopamine re-uptake inhibitors.
在小鼠中研究了多巴胺再摄取抑制剂安非他酮和诺米芬辛对强迫游泳试验中不动时间的影响。安非他酮和诺米芬辛剂量依赖性地减少了不动时间。两种药物在不改变运动活性的剂量下均显著表现出抗不动作用。多巴胺D1受体拮抗剂R-(+)-7-氯-8-羟基-3-甲基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓盐酸盐(SCH 23390)和多巴胺D2受体拮抗剂舒必利抑制了安非他酮和诺米芬辛的抗不动作用。这些发现表明多巴胺可能与抑郁症有关,并且多巴胺D1和多巴胺D2受体在多巴胺再摄取抑制剂的作用中发挥作用。